Iovance Biotherapeutics is a commercial-stage biopharmaceutical company pioneering the development and commercialization of tumor-infiltrating lymphocyte (TIL) cell therapies for patients with solid t... Iovance Biotherapeutics is a commercial-stage biopharmaceutical company pioneering the development and commercialization of tumor-infiltrating lymphocyte (TIL) cell therapies for patients with solid tumor cancers. The company's approach harnesses the immune system's natural ability to recognize and attack cancer cells by isolating a patient's tumor-infiltrating lymphocytes, expanding them outside the body, and reinfusing them as a personalized, one-time treatment. Iovance's marketed product, Amtagvi (lifileucel), is the first FDA-approved autologous T-cell therapy for unresectable or metastatic melanoma, particularly for patients who have been treated with anti-PD-1 therapies. The company is advancing clinical programs investigating lifileucel and other TIL therapies across multiple advanced solid tumors, including cervical cancer, non-small cell lung cancer, endometrial cancer, and head and neck squamous cell carcinoma. Iovance manufactures its therapies at a state-of-the-art cell therapy center in Philadelphia using proprietary manufacturing processes and collaborates with leading research institutions and pharmaceutical partners to expand its pipeline.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Iovance Biotherapeutics is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Iovance Biotherapeutics is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Iovance Biotherapeutics's data?

Start your 30-day free trial to request a data review for Iovance Biotherapeutics.

Start Free Trial

Legal Center Contact Us

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is not subject to EU Taxonomy reporting

Account Restricted